Information Provided By:
Fly News Breaks for March 18, 2019
ARGX, MNTA
Mar 18, 2019 | 06:42 EDT
BTIG analyst Thomas Shrader initiated Momenta (MNTA) with a Neutral rating, saying that while he is positive on the company's IVIg-focused re-positioning, the stock is not cheap and the proof-of-concept for its analytical focus is at least a year away. The analyst also states that the bulk of his modeled value for the company comes from its pipeline development in treating maternal-fetal autoimmune disease, noting that competition in the space is "fierce" and that Momenta is "significantly behind Argenx (ARGX) in the development of FcRn blockers.
News For MNTA;ARGX From the Last 2 Days
ARGX
Mar 27, 2024 | 16:07 EDT
Oppenheimer initiated coverage of Immunovant (IMVT) with an Outperform rating and $50 price target. The firm sees Immunovant "shifting the balance of power" from Argenx (ARGX) as its anti-FcRn antibody candidates advance toward the market and looks forward to a series of late-stage trial readouts on lead asset batoclimab over the coming year, the analyst tells investors. The firm believes batoclimab's dosing flexibility and administration simplicity offer favorable differentiation from Vyvgart, the analyst added.